Pharvaris Short Term Debt Over Time
| PHVS Stock | USD 21.04 0.54 2.63% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Pharvaris Performance and Pharvaris Correlation. Pharvaris |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pharvaris. If investors know Pharvaris will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pharvaris listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.74) | Return On Assets (0.27) | Return On Equity (0.45) |
The market value of Pharvaris BV is measured differently than its book value, which is the value of Pharvaris that is recorded on the company's balance sheet. Investors also form their own opinion of Pharvaris' value that differs from its market value or its book value, called intrinsic value, which is Pharvaris' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pharvaris' market value can be influenced by many factors that don't directly affect Pharvaris' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pharvaris' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pharvaris is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pharvaris' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Short Term Debt Analysis
Compare Pharvaris BV and related stocks such as Pmv Pharmaceuticals, Eliem Therapeutics, and MediciNova Short Term Debt Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PMVP | 806 K | 806 K | 806 K | 806 K | 806 K | 806 K | 806 K | 806 K | 806 K | 806 K | 806 K | 806 K | 1.1 M | 1.7 M | 1.3 M |
| MNOV | 17.6 M | 1.7 B | 1.7 B | 1.7 B | 1.7 B | 1.7 B | 1.7 B | 1.7 B | 1.7 B | 1.7 B | 1.7 B | 132 K | 157.5 K | 215.9 K | 205.1 K |
| PEPG | 11.1 M | 11.1 M | 11.1 M | 11.1 M | 11.1 M | 11.1 M | 11.1 M | 11.1 M | 11.1 M | 11.1 M | 11.1 M | 11.1 M | 11.1 M | 6 M | 6.8 M |
| MOLN | 4.7 M | 4.7 M | 4.7 M | 4.7 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.2 M | 1.2 M | 1.2 M | 1.2 M | 1.4 M |
| MLYS | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4 M | 3.6 M |
| ANTX | 106 K | 106 K | 106 K | 106 K | 106 K | 106 K | 106 K | 106 K | 106 K | 106 K | 106 K | 106 K | 106 K | 95.4 K | 84.8 K |
| GLUE | 750 K | 750 K | 750 K | 750 K | 750 K | 750 K | 750 K | 750 K | 750 K | 750 K | 6.3 M | 6.3 M | 6.3 M | 6.3 M | 4.9 M |
| DSGN | 695 K | 695 K | 695 K | 695 K | 695 K | 695 K | 695 K | 695 K | 695 K | 695 K | 489 K | 489 K | 640 K | 716 K | 698.5 K |
| HOWL | 595 K | 595 K | 595 K | 595 K | 595 K | 595 K | 595 K | 595 K | 595 K | 595 K | 677 K | 2.1 M | 4.2 M | 8.3 M | 8.7 M |
| IKNA | 2.6 M | 2.6 M | 2.6 M | 2.6 M | 2.6 M | 2.6 M | 2.6 M | 2.6 M | 2.6 M | 2.6 M | (17.6 M) | 3.7 M | 3.8 M | 7.1 M | 7.5 M |
| STOK | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.1 M | 1.1 M | 1.5 M | 2.4 M | 2.1 M | 1.3 M |
| TYRA | 139 K | 139 K | 139 K | 139 K | 139 K | 139 K | 139 K | 139 K | 139 K | 139 K | 142 K | 404 K | 280 K | 560 K | 335.5 K |
| ANEB | 201.3 K | 201.3 K | 201.3 K | 201.3 K | 201.3 K | 201.3 K | 201.3 K | 201.3 K | 201.3 K | 201.3 K | 201.3 K | 201.3 K | 201.3 K | 181.2 K | 161 K |
| JANX | 4 M | 4 M | 4 M | 4 M | 4 M | 4 M | 4 M | 4 M | 4 M | 4 M | 751 K | 388 K | 1.5 M | 1.5 M | 1.3 M |
| RZLT | 3.7 M | 3.7 M | 3.7 M | 60 K | 153.9 K | 83.1 K | 10 K | 3.4 M | 10 K | 245 K | 530 K | 108 K | 541 K | 568 K | 631.7 K |
Pharvaris BV and related stocks such as Pmv Pharmaceuticals, Eliem Therapeutics, and MediciNova Short Term Debt description
My Equities
My Current Equities and Potential Positions
| Pharvaris BV | PHVS |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Netherlands |
| Exchange | NASDAQ Exchange |
USD 21.04
Additional Tools for Pharvaris Stock Analysis
When running Pharvaris' price analysis, check to measure Pharvaris' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharvaris is operating at the current time. Most of Pharvaris' value examination focuses on studying past and present price action to predict the probability of Pharvaris' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharvaris' price. Additionally, you may evaluate how the addition of Pharvaris to your portfolios can decrease your overall portfolio volatility.